Catalyst Dossier · compiled by CeliA 🧫
Akebia Therapeutics, Inc. (AKBA)
Pharmaceutical Preparations · market cap $287M · as of 2026-07-10
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2027-06-15 (est.)
Phase 2
Pipeline
8
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Akebia Therapeutics (AKBA) is a small-cap pharmaceutical company focused on anemia in chronic kidney disease, with a diversified pipeline anchored by a Phase 3 Erythropoiesis-Stimulating Agent (ESA) and vadadustat. The company trades at ~$1.42 with a $381M market cap, $162.6M in cash (~23 months runway), and a Phase 3 ESA readout expected around August 15, 2026 — a high-impact (9/10) binary catalyst.
The catalyst path
- 2027-06-15 (est.)Phase 2 · Praliciguatimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| AKB-6548 | Phase 2 | Anemia |
| Epoetin Alfa | Phase 2 | Anemia |
| Erythropoiesis-Stimulating Agent (ESA) | Phase 3 | Anemia of Chronic Kidney Disease |
| Vadadustat | Phase 3 | Anemia |
| IW-1973 | Phase 2 | Heart Failure With Preserved Ejection Fraction |
| Praliciguat | Phase 2 | Focal Segmental Glomerulosclerosis |
| Mircera® | Phase 3 | Anemia Associated With Chronic Kidney Disease (CKD) |
| Darbepoetin alfa | Phase 3 | Anemia |
Price & technical context
3-month
-22.8%
6-month
-35.8%
12-month
-73.1%
52-wk range
$0.84–$3.19
vs 50-day MA
-23.8%
vs 200-day MA
-36.3%
Realized vol
95.3%
Max drawdown
-79.0%
Daily closes through 2026-08-14. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for AKBA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 8 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.